Abiopharma

SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041

Hydrafacial Introduces HydraScalp® with Keravive™ as Next Evolution in Scalp Health

Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Trident Digital Tech Holdings Launches TDTHAI Across Asia-Pacific to Accelerate Enterprise AI Deployment and Digital Infrastructure Growth

Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026

QuickLogic Set to Join Russell 2000® and Russell 3000® Indexes

Fluent Inc. Subsidiary Trevant Launches as Creator Marketing Agency Built on Performance Discipline

Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026

Bristol Myers Squibb - Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma

RedHill Biopharma - RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms